REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
11/07/2026
Voltar para busca
Dado oficial do USPTO
HEPTARES
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
HEPTARES
ST13
US500000086577541Classe
1, 5, 42, 44
Pedido
86577541
Registro
5239010
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
50
Atualização mais recente
11/07/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42, 44
Data de depósito
26/03/2015
Data de registro
11/07/2017
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
02/01/2024
Última transação
11/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
705
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Código do desenho
4
Tipo de titular
99
Localização do titular
TOKYO, JP
Examinador
HUNT, LEE
Unidade examinadora
M60
Titulares e representantes
Titulares
NXERA PHARMA CO., LTD
SOSEI GROUP CORPORATION
Heptares Therapeutics Limited
Heptares Therapeutics Limited
Representantes
Rebecca Liebowitz VENABLE LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicals and proteins used in researchfor chemistry and biological drug discoverylead identification and diagnostics; proteins including G-protein-coupled receptorstrans-membrane proteins and parts thereoffor use in pharmaceutical researchdrug discovery purposes
Classe 5
Biological products for medical purposesg-protein-coupled receptorstransmembrane proteins and parts thereof for use in chemical and biological drug discoverylead identificationdiagnostics and therapeutic purposes; biological and chemical products for medical useproteinsG-protein-coupled receptorstransmembrane proteinsG-Proteinsantibodies and peptides and parts thereoffor therapeutic purposes; chemicalsproteins and parts thereof for use in medical diagnostics; none being dietetic substances adapted for medical use or food products
Classe 42
Biotechnology testinggenetic testing for scientific research purposes; Biotechnology research; Biotechnology developmentdevelopment in the field of drug discovery and biopharmaceuticals; biotechnology advice; Biotechnology consultancy; Biotechnology informationproviding information on the subject of scientific research in the field of biotechnology; Pharmaceutical testing; pharmaceutical research; pharmaceutical development; pharmaceutical consultancy for non-medical purposes; Providing medical and scientific research information in the fields of pharmaceuticals; scientific testing and research in the pharmaceutical and biopharmaceutical fieldschemical and biological drug discovery services; providing scientific informationadviceconsultancy in the field of technologies related to proteinsincluding transmembrane proteins and G-proteinsG protein coupled receptorsparts thereof; bio-technologypharmaceutical and scientific testingresearchdevelopmentadviceconsultancy and information services; biological research; Research and development in the pharmaceutical and biopharmaceutical fieldstechnologies related to proteins and G protein coupled receptors; biology and chemistry servicesresearch and consulting in the field of chemistry and biology; pharmaceutical research serviceschemical and biological drug discovery services; research and development services for pharmaceutical lead identification; synthetic chemistry consultation services and research; research and development services in the creation of libraries or collections of biologicalschemicals and compounds; researchcreationdevelopment and provision of chemical and biological drug targets for non-medical screening purposes; researchanalysis and identification of compounds through automated screening processes research and development services relating to pharmaceutical research serviceschemical and biological drug discovery services
Classe 44
Pharmaceutical advice; pharmaceutical consultancy for medical purposes; providing information relating to diagnosticprophylactic and therapeutic properties of pharmaceuticals; researchcreationdevelopment and provision of chemical and biological drug targets for medical screening purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
50 publicações encontradas
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
04/07/2024
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
02/01/2024
C15P
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
02/01/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
02/01/2024
E815
TEAS SECTION 8 & 15 RECEIVED
10/07/2023
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
11/07/2022
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
06/05/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
30/10/2018
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
30/10/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
11/07/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
25/04/2017
PUBO
PUBLISHED FOR OPPOSITION
25/04/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/04/2017
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
17/03/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/03/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/02/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/02/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/02/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/08/2016
GNRT
NON-FINAL ACTION E-MAILED
05/08/2016
CNRT
NON-FINAL ACTION WRITTEN
05/08/2016
GNS1
NOTIFICATION OF SUBSEQUENT FINAL EMAILED
07/07/2016
GNSF
SUBSEQUENT FINAL EMAILED
07/07/2016
CFRC
SUBSEQUENT FINAL REFUSAL WRITTEN
07/07/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
15/06/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
15/06/2016
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
15/06/2016
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
08/03/2016
GNFR
FINAL REFUSAL E-MAILED
08/03/2016
CNFR
FINAL REFUSAL WRITTEN
08/03/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/02/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/02/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
16/02/2016
GAUN
NOTIFICATION OF NOTICE OF UNRESPONSIVE AMENDMENT - E-MAILED
20/01/2016
GAUD
NOTICE OF UNRESPONSIVE AMENDMENT - E-MAILED
20/01/2016
NAUD
REPORT UNRESPONSIVE AMENDMENT - COMPLETED
20/01/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
20/01/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/01/2016
ALIE
ASSIGNED TO LIE
15/01/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/01/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/07/2015
GNRT
NON-FINAL ACTION E-MAILED
12/07/2015
CNRT
NON-FINAL ACTION WRITTEN
12/07/2015
DOCK
ASSIGNED TO EXAMINER
29/06/2015
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
05/06/2015
ALIE
ASSIGNED TO LIE
01/06/2015
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
27/05/2015
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/04/2015
NWAP
NEW APPLICATION ENTERED
30/03/2015
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace HEPTARES ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.